|
Breast cancer subtypes according to disease status. |
||||
| IHC subtype |
No. (%) |
p Value† |
||
|
|
||||
| Patients with EBC (n = 118) |
Patients with MBC* (n = 556) |
Patients with BM (n = 126) |
||
|
|
||||
| Luminal A (ER or PR+/HER2-) |
68 (57.6) |
254 (46.7) |
23 (18.3) |
< 0.0001 |
| Luminal B (ER or PR+/HER2+) |
16 (13.6) |
73 (13.1) |
19 (15.1) |
|
| HER2+/ER- (ER-/PR-/HER2+) |
15 (12.7) |
91 (16.4) |
37 (29.4) |
|
| Triple-negative (ER-/PR-/HER2-) |
19 (16.1) |
138 (24.8) |
47 (37.3) |
|
|
Abbreviations: BM, brain metastases; EBC, early breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; IHC, immunohistochemistry; MBC, metastatic breast cancer; PR, progesterone receptor. *Excluding patients with brain metastases. †Comparing three groups (patients with EBC, patients with MBC other than BM, and patients with BM) using the chi-square test. | ||||
Nam et al. Breast Cancer Research 2008 10:R20 doi:10.1186/bcr1870 |
||||